Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases

Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases

Autoimmune disease development depends on multiple factors, including genetic and environmental. Abnormalities such as sialylation levels and/or quality have been recently highlighted. The adjunction of sialic acid at the terminal end of glycoproteins and glycolipids is essential for distinguishing...

Full description

Bibliographic Details
Main Authors: Anne Bordron, Marie Morel, Cristina Bagacean, Maryvonne Dueymes, Pierre Pochard, Anne Harduin-Lepers, Christophe Jamin, Jacques-Olivier Pers
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
sialic acid
sialyltransferase
autoimmune diseases
immunoglobulin
CD22
therapies
Online Access:https://www.mdpi.com/1422-0067/22/7/3402

Internet

https://www.mdpi.com/1422-0067/22/7/3402

Similar Items